Skip to content
Clinical Trials – home

Kardiologische Praxis Dr. med. Ayham Al-Zoebi Wermsdorf

Verified siteinfo

Germany Clara-Zetkin-Strasse 23, 04779 Wermsdorf, Germany

  • 7 trials recruiting
  • Hypertension · Cardiac failure · Cardiovascular disorder
  • Adult patients

About Specializations

Kardiologische Praxis Dr. med. Ayham Al-Zoebi Wermsdorf in Wermsdorf, Germany specialises in clinical trials of conditions such as Hypertension, Cardiac failure, Cardiovascular disorder, Atrial fibrillation, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Research

The medical center is at the forefront of cardiovascular research, focusing on innovative treatments for hypertension. The center's work is pivotal in understanding and managing uncontrolled hypertension and resistant hypertension, conditions that pose significant challenges in clinical practice.

  • Hypertension Management
  • Innovative Therapeutics
  • Patient-Centric Approaches

Through its cutting-edge research, the center contributes to the development of new therapeutic strategies that aim to improve patient outcomes and enhance the quality of life for individuals with complex cardiovascular conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Clara-Zetkin-Strasse 2304779 WermsdorfGermany
Recruiting now
7 trials
Conditions studied
10
Partner status
Verified site

More sites in WermsdorfGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

13 clinical trials

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Study on the Effects of Baxdrostat and Dapagliflozin in Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Cardiac failure

Recruiting

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Cardiac failure+1

Recruiting

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Novo Nordisk A/S

Cardiac failure

Recruiting

Evaluating the Effect of Vicadrostat and Empagliflozin Combination Compared to Empagliflozin Alone in Patients with Heart Failure and Reduced Left Ventricular Function

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Atrial fibrillation

Not yet recruiting

Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:REGN7508
  • Sponsor:Regeneron Pharmaceuticals Inc.

A study testing cagrilintide and semaglutide for heart safety in people with cardiovascular disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Cardiac failure

Not recruiting

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Atrial fibrillation

Not recruiting

Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Andexanet Alfa
  • Sponsor:Janssen Cilag International

Hypertension

Not recruiting

Study on Baxdrostat for Reducing Blood Pressure in Patients with Uncontrolled or Resistant Hypertension

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.